Thursday, 10 August 2017 08:00 AM
NEW YORK, NY / ACCESSWIRE / August 10, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report with no obligation on Molecular Templates, Inc. (NASDAQ: MTEM) a clinical-stage biopharmaceutical company focused on the development of drugs and diagnostic agents targeting the tumor microenvironment of solid tumors and hematologic malignancies. The company was formerly known as Threshold Pharmaceuticals, Inc., a NASDAQ listed company.
On August 1st, 2017, Threshold announced the merger with Molecular Templates, Inc. Following the completion of the merger, Threshold changed its name to Molecular Templates, Inc. Apart from operational & financial synergies, the merger is expected to result in re-evaluation by analysts of the merged entity over the near term. Additionally, the deal is expected to bridge some part of the valuation gap of the standalone entities.
The combined company has a Unique Biological Platform with a differentiated mechanism of action in oncology and two clinical-stage candidates, MT-3724 and Evofosfamide. As per management, the merger has triggered an exciting step in the evolution of Molecular Templates as it enters the public markets.
Our full report gives all the merger details, outlook for the combination, pipeline review and catalysts READ MORE
Copy and paste to your browser may be required to view the report - http://tradersnewssource.com/mtem/
Molecular Templates is focused on the discovery, development and commercialization of next-generation immunotoxins called Engineered Toxin Bodies (ETBs) for the treatment of cancers and other serious diseases.
On August 3rd, the merged entity announced a collaboration agreement for oncology drug discovery programs. The collaboration will apply Molecular Templates' engineered toxin bodies (ETB) technology platform to potential therapeutic targets provided by Takeda Pharmaceutical Company Limited through a joint scientific committee of both companies.
Under the terms of the agreement, Takeda will make an equity investment and Molecular Templates is eligible to receive upfront payments, as well as development and commercial milestone payments. Takeda has agreed to royalties on the sales of commercial products developed through the collaboration.
Our full report details the drug pipeline and explores the synergies of the merger READ MORE
Copy and paste to your browser may be required to view the report - http://tradersnewssource.com/mtem/
DISCLOSURE
Traders News Source LLC (TNS) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering small and micro-cap equity markets. TNS has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE, NASDAQ and OTC exchanges. The other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
TNS has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a chartered financial analyst, for further information on analyst credentials, please email [email protected]. Vikas Agrawal, a CFA® charter holder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written, and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author per the procedures outlined by TNS. TNS is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents, or reports. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
TNS, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake, or shortcoming. No liability is accepted whatsoever for any direct, indirect, or consequential loss arising from the use of this document. TNS, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, TNS, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness, or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither TNS nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://www.tradersnewssource.com.
For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer be featured on our coverage list, contact us via email at: [email protected]
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
CONTACT:
SOURCE: Traders News Source